izpis_h1_title_alt

Overcoming drug impurity challenges in amorphous solid dispersion with rational development of biorelevant dissolution-permeation method
ID Huzjak, Tilen (Author), ID Jakasanovski, Ognen (Author), ID Berginc, Katja (Author), ID Puž, Vid (Author), ID Zajc-Kreft, Katarina (Author), ID Jeraj, Žiga (Author), ID Janković, Biljana (Author)

.pdfPDF - Presentation file, Download (1,98 MB)
MD5: DADD2338D2320295D1A14229F5BC2F9D
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0928098723002841 This link opens in a new window

Abstract
Hot-melt extrusion is often used to prepare amorphous solid dispersion to overcome low drug solubility and enhance bio-performance of the formulation. Due to the uniqueness of each drug - polymer combination and its physico-chemical properties, setting the appropriate HME barrel temperature, feed rate and screw speed ensures drug amorphization, absence of residual crystallinity, absence of water, and a suitable drug release profile. In this research, samples with BCS II/IV model drug and PVP/VA polymer were prepared to evaluate the impact of HME process parameters, incoming drug form (anhydrous vs. hydrate), and drug supplier (i.e., impurity profile), on biorelevant drug release. This study provides a relationship between observed in vitro supersaturation and precipitation behavior of amorphous solid dispersion formulation with in vivo results, on patients, by using the acceptor profile of side-by-side dissolution-permeation apparatus. An in vitro dissolution method, in small volumes, in an apparatus with paddles and dissolution-permeation side-by-side method was developed on the MicroFlux™ apparatus to assess if the differences observed in vitro bears relevance to the bioequivalence outcome in vivo. The former was used to guide the generic drug product development due to high discriminatory strength, while the latter was biorelevant, due to the inclusion of the second compartment assuring absorptive environment to capture the impact of supersaturation and subsequent precipitation on bioavailability. Bio-relevancy of the in vitro method was confirmed with the in vivo dog study and clinical study on patients, and an in vitro - in vivo correlation was established. For the investigated BCS II/IV drug, this research highlights the importance of considering supersaturation and formation of colloidal species during amorphous solid dispersion release testing to assure product quality, safety and efficacy.

Language:English
Keywords:biorelevant dissolution-permeation, hot-melt extrusion, In vitro – in vivo correlation, liquid-liquid phase separation, solid dispersion, supersaturation
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:12 str.
Numbering:Vol. 192, art. 106655
PID:20.500.12556/RUL-155631 This link opens in a new window
UDC:544.351.3:615.45
ISSN on article:0928-0987
DOI:10.1016/j.ejps.2023.106655 This link opens in a new window
COBISS.SI-ID:188116227 This link opens in a new window
Publication date in RUL:09.04.2024
Views:454
Downloads:202
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:European Journal of Pharmaceutical Sciences
Shortened title:Eur. j. pharm. sci.
Publisher:Elsevier
ISSN:0928-0987
COBISS.SI-ID:17553413 This link opens in a new window

Licences

License:CC BY-ND 4.0, Creative Commons Attribution-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nd/4.0/
Description:Under the NoDerivatives Creative Commons license one can take a work released under this license and re-distribute it, but it cannot be shared with others in adapted form, and credit must be provided to the author.

Secondary language

Language:Slovenian
Keywords:farmacevtske oblike, topnost, biorelevantno raztapljanje-prepustnost, ekstrudiranje z vročim taljenjem, in vitro – in vivo korelacija, ločevanje tekoče-tekoče faze, trdna disperzija, prenasičenost

Projects

Funder:Other - Other funder or multiple funders
Project number:MA-16430-2020

Funder:ARRS - Slovenian Research Agency
Project number:P1-0189
Name:Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back